Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2011

01-08-2011 | Stanford Multidisciplinary Seminars

Acute Liver Failure and Aplastic Anemia in an 11-Year-Old Girl

Authors: Ann Ming Yeh, Amirkaveh Mojtahed, Dorsey Bass

Published in: Digestive Diseases and Sciences | Issue 8/2011

Login to get access

Excerpt

An 11-year-old previously healthy female presented with a 1-week history of jaundice and fatigue. Her aspartate aminotransferase (AST) level was 1,420 U/L, alanine aminotransferase (ALT) 1,044 U/L, total bilirubin 16.5 mg/dL and international normalized ratio (INR) for prothrombin time 1.2. Complete blood count showed a white blood count of 7,700/mm3, hematocrit 40.6 g/dL, and platelet count 509,000/mm3. Ultrasound demonstrated mild hepatomegaly but was otherwise normal. Serology was negative for hepatitis A, B, and C and Epstein-Barr virus (EBV) and cytomegalovirus (CMV). After discharge, she was followed by her outpatient pediatric gastroenterologist, who noted that she continued to have jaundice and elevated aminotransferase levels. A liver biopsy was recommended, but her parents refused, and the patient was lost to follow-up for several months. …
Literature
1.
go back to reference Hadzić N, Height S, Ball S, et al. Evolution in the management of acute liver failure-associated aplastic anaemia in children: a single centre experience. J Hepatol. 2008;48:68–73.PubMedCrossRef Hadzić N, Height S, Ball S, et al. Evolution in the management of acute liver failure-associated aplastic anaemia in children: a single centre experience. J Hepatol. 2008;48:68–73.PubMedCrossRef
2.
go back to reference Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R. Systematic review: hepatitis-associated aplastic anaemia—a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009;30:436–443.PubMedCrossRef Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R. Systematic review: hepatitis-associated aplastic anaemia—a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009;30:436–443.PubMedCrossRef
3.
go back to reference Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis-associated aplastic anemia. N Engl J Med. 1997;336:1059–1064.PubMedCrossRef Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis-associated aplastic anemia. N Engl J Med. 1997;336:1059–1064.PubMedCrossRef
4.
go back to reference Safadi R, Or R, Ilan Y, et al. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation. Bone Marrow Transpl. 2001;27:183–190.CrossRef Safadi R, Or R, Ilan Y, et al. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation. Bone Marrow Transpl. 2001;27:183–190.CrossRef
5.
go back to reference Cengiz C, Turhan N, Yolcu OF, Yilmaz S. Hepatitis associated with aplastic anemia: do CD8(+) kupffer cells have a role in the pathogenesis? Dig Dis Sci. 2007;52:2438–2443.PubMedCrossRef Cengiz C, Turhan N, Yolcu OF, Yilmaz S. Hepatitis associated with aplastic anemia: do CD8(+) kupffer cells have a role in the pathogenesis? Dig Dis Sci. 2007;52:2438–2443.PubMedCrossRef
6.
go back to reference Marsh J, Ball S, Darbyshire P, et al. Guideline guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol. 2003;123:782–801.PubMedCrossRef Marsh J, Ball S, Darbyshire P, et al. Guideline guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol. 2003;123:782–801.PubMedCrossRef
7.
go back to reference Lu J, Basu A, Melenhorst JJ, Young NS, Brown KE. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood. 2004;103:4588–4593.PubMedCrossRef Lu J, Basu A, Melenhorst JJ, Young NS, Brown KE. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood. 2004;103:4588–4593.PubMedCrossRef
8.
go back to reference Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006;107:3983–3991.PubMedCrossRef Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006;107:3983–3991.PubMedCrossRef
9.
go back to reference Osugi Y, Yagasaki H, Sako M, et al. Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. Haematologica. 2007;92:1687–1690.PubMedCrossRef Osugi Y, Yagasaki H, Sako M, et al. Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. Haematologica. 2007;92:1687–1690.PubMedCrossRef
10.
go back to reference Molleston JP, Vik TA, Steiner SJ, Kernek KM. Non-ABC acute hepatic failure associated with aplastic anemia can be treated with immunosuppression. J Pediatr Gastroenterol Nutr. 2008;46:216–219.PubMedCrossRef Molleston JP, Vik TA, Steiner SJ, Kernek KM. Non-ABC acute hepatic failure associated with aplastic anemia can be treated with immunosuppression. J Pediatr Gastroenterol Nutr. 2008;46:216–219.PubMedCrossRef
11.
go back to reference Tung J, Hadzic N, Layton M, et al. Bone marrow failure in children with acute liver failure. J Pediatr Gastroenterol Nutr. 2000;31:557–561.PubMedCrossRef Tung J, Hadzic N, Layton M, et al. Bone marrow failure in children with acute liver failure. J Pediatr Gastroenterol Nutr. 2000;31:557–561.PubMedCrossRef
Metadata
Title
Acute Liver Failure and Aplastic Anemia in an 11-Year-Old Girl
Authors
Ann Ming Yeh
Amirkaveh Mojtahed
Dorsey Bass
Publication date
01-08-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1678-y

Other articles of this Issue 8/2011

Digestive Diseases and Sciences 8/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine